Search

Tesamorelin Online: Egrifta vs Compounded, and What It Costs

Tesamorelin is the only growth-hormone-releasing hormone (GHRH) analog with a current FDA approval, and that approval is narrow: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Here is what it costs online, what the trials showed, and how it differs from sermorelin. The FDA label doses are on our tesamorelin profile, linked below.

The short answer

From 11 sources
  • Compounded, online: we list no compounded tesamorelin seller. FDA has regulated tesamorelin as a biological product since March 23, 2020, and biologics are not eligible for the 503A and 503B compounding exemptions.
  • Brand-name Egrifta WR: about $11,030 a month (one 28-day kit) at a cash price (Drugs.com listing, Oct 29, 2026). Insurance usually covers it only for the approved HIV indication.
  • Tesamorelin vs sermorelin: tesamorelin has an FDA approval and phase 3 visceral-fat trials; sermorelin has no approved product today but costs less online, from $99/mo.

Tesamorelin prices

Sorted by the lowest published monthly cost. Affiliate status never changes the order.

Every price we found

1 offer · checked Oct 29, 2026
Price from a Drugs.com cash-price listing, checked Oct 29, 2026. We list no compounded seller: as a biologic, tesamorelin is not eligible for the 503A and 503B compounding exemptions.
SellerProductPriceStatusIncludes
Egrifta WR (Theratechnologies)Brand tesamorelin, 1 kit = 4 vials, a 28-day supplyAbout $11,030 per kit, cash (Drugs.com listing)seller's list priceFDA-approved brandMedication only. Approved only for HIV-associated lipodystrophy; insurance or the maker’s THERA co-pay program may lower the cost for that use
"Starting at" prices can change after a clinician sets your dose. A link to a seller is either a paid link, which earns us a commission if you buy through it, or a plain link to a program we have applied to; other sellers are listed as plain text, for price context only.

What the trials showed, and for whom

Two 26-week, placebo-controlled phase 3 trials enrolled 816 adults with HIV on stable antiretroviral therapy and excess abdominal fat. Daily 2 mg tesamorelin cut visceral fat (measured by CT) by 18% and 14% in the two studies, against +2% and −2% on placebo (Egrifta WR label). In the first trial, published in NEJM, triglycerides and the cholesterol-to-HDL ratio also improved.

In a pooled analysis, fat under the skin of the abdomen did not change significantly over the first 26 weeks, and in patients who kept taking tesamorelin the visceral-fat reduction held through 52 weeks. Body weight barely moved: the label calls the effect weight-neutral.

These trials studied one population: adults with HIV-associated lipodystrophy. They do not show what tesamorelin does for people without that condition, and we make no claims about other uses.

Tesamorelin vs sermorelin: the differences that matter

Both are GHRH analogs that prompt the pituitary to release growth hormone. Neither is better for everyone; the differences are approval, evidence, cost and monitoring.

Tesamorelin vs sermorelin. Prices checked Oct 29, 2026 (Egrifta WR on Drugs.com, sermorelin on Embody’s own site); label facts from FDA.
TesamorelinSermorelin
FDA statusApproved as Egrifta for excess abdominal fat in adults with HIV-associated lipodystrophy onlyNo approved product. Geref was discontinued in 2008; FDA found it was not withdrawn for safety or effectiveness
What telehealth sellsCompounded (no FDA compounding pathway for a biologic) or brand Egrifta by prescriptionCompounded only
Molecule44-amino-acid GHRH analogThe first 29 amino acids of GHRH
Visceral-fat evidenceTwo 26-week phase 3 trials in HIV lipodystrophy (816 patients)Its former approval (Geref) was for children with growth hormone deficiency; never approved for visceral fat
Online costEgrifta WR about $11,030/mo cash (one 28-day kit); we list no compounded sellerFrom $99/mo after a $49 first month (Embody); see our sermorelin page
MonitoringLabel: check IGF-1 during treatment and glucose before and during; consider stopping if IGF-1 stays highNo current US label; monitoring varies by clinic
ContraindicationsLabel: disrupted hypothalamic-pituitary axis, active cancer, hypersensitivity, pregnancyNo current US label; ask the prescriber
Tested athletesProhibited (WADA S2.2.4)Prohibited (WADA S2.2.4)

Safety points from the FDA label

  • Raises IGF-1, a growth factor; the effect of long-term high IGF-1 is unknown, so the label says to monitor it.
  • Can cause glucose intolerance or diabetes: in the trials, 5% on tesamorelin vs 1% on placebo developed an HbA1c of 6.5% or higher.
  • Fluid retention (swelling, joint pain, carpal tunnel), injection-site reactions and hypersensitivity reactions.
  • Not for use with active cancer, a disrupted hypothalamic-pituitary axis (for example after pituitary surgery or radiation), or in pregnancy.

Who shouldn’t buy it online

Tested athletes (WADA prohibits it at all times), anyone with active cancer, a disrupted hypothalamic-pituitary axis or a pregnancy, anyone told to avoid growth-hormone-related treatment, and anyone offered “research use only” vials instead of a prescription.

Questions

Common questions

5 answers
Is tesamorelin FDA-approved?

Yes, but only as Egrifta (Egrifta SV and Egrifta WR) for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The label says it is not for weight-loss management. Other uses are off-label, and compounded tesamorelin is not FDA-approved.

How much does tesamorelin cost online?

On Oct 29, 2026, brand-name Egrifta WR listed at about $11,030 a month (one 28-day kit) at a cash price on Drugs.com; insurance may cover it for the approved HIV indication. We list no compounded tesamorelin seller: FDA has regulated tesamorelin as a biological product since March 23, 2020, and biologics are not eligible for the 503A and 503B compounding exemptions.

Is tesamorelin better than sermorelin?

Not across the board. Tesamorelin has an FDA approval and phase 3 trials showing visceral-fat reduction in adults with HIV-associated lipodystrophy. Sermorelin has no approved product today but costs less online. Which fits depends on your health, goals and budget; a clinician should decide.

Do I need labs for tesamorelin?

The Egrifta label says to monitor IGF-1 during treatment and to check glucose before and during therapy. Ask any online provider what labs they order and how often.

Can athletes use tesamorelin?

No for tested athletes: WADA lists tesamorelin by name under growth hormone releasing factors (S2.2.4), prohibited in and out of competition.

Regulatory status

Regulatory status

Tesamorelin is FDA-approved only under the Egrifta name (Egrifta, Egrifta SV and Egrifta WR), for reducing excess abdominal fat in adults with HIV and lipodystrophy. The label says it is not indicated for weight-loss management, and long-term cardiovascular safety has not been established. Any other use is off-label.

Since March 23, 2020, FDA has regulated tesamorelin as a biological product, and FDA says biologics are not eligible for the compounding exemptions in sections 503A and 503B. Compounded tesamorelin is not FDA-approved; ask any provider which product and which pharmacy would fill your prescription.

Medical disclaimer

Not medical advice. Outside HIV-associated lipodystrophy, tesamorelin has no FDA-reviewed indication. A licensed clinician decides whether it is appropriate for you; individual results vary.

Educational only. Not medical advice.

We earn a commission on some links. That never changes a rank. How we make money: kymatahealth.com/affiliate-disclosure.